Navigation Links
Symphony Medical Changes Name to CardioPolymers, Inc.
Date:7/22/2009

LAGUNA HILLS, Calif., July 22 /PRNewswire/ -- Symphony Medical, Inc., a development-stage company focused on novel biopolymer implant therapies to treat cardiac abnormalities, announced today that it has changed the name of the corporation to CardioPolymers, Inc.

CardioPolymers, Inc. Chief Executive Officer Raymond W. Cohen said, "The name change, which is effective immediately, better reflects our focus on employing natural biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle."

CardioPolymers is currently sponsoring a human clinical study of its patented flagship technology Algisyl-LVR(R) at world-class centers in Europe, including the German Heart Center in Munich where the first three patients were successfully treated.

Algisyl-LVR is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in which the heart becomes weakened and enlarged, and cannot pump blood efficiently. The procedure involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to re-shape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.

About CardioPolymers, Inc.

CardioPolymers, Inc., a Delaware Corporation (formerly known as Symphony Medical) was founded in 2003 and is headquartered in Orange County, California. The Company is privately held and backed by venture investors Johnson & Johnson, Domain Associates, Morgenthaler Ventures, Triathlon Medical Ventures and Fjord Ventures. The development stage company is developing proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders.

For more information on CardioPolymers, Inc. please visit our website at

www.symphonymed.com

    Contact:  Matt Clawson
              Allen & Caron Inc
              949-474-4300
              matt@allencaron.com


'/>"/>
SOURCE CardioPolymers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Symphony Managemnt Consulting Hires New Solutions Director
3. Angiotech and Symphony Medical Announce Licensing Agreement
4. Environmental Tectonics Corporation Announces Promotion of Don R. Webber to VP of Sales for their BioMedical Division
5. Regado Biosciences Expands Medical Advisory Board
6. BioMS Medical announces second quarter 2009 results
7. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
8. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
9. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
10. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
11. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Scientists at ... line options being tried for mesothelioma may be hampering the research that could lead ... research. Click here to read it now. , The team evaluated 98 ...
(Date:5/24/2016)... ... 24, 2016 , ... Cell therapies for a range of ... research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method of ... The novel method, developed by WPI faculty members Raymond Page, PhD, professor of ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Frontage Boost Efficiency by 40% - Frontage Implement a ... Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... in the United States and ... be deployed across its laboratory facilities. In addition to serving as ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):